GLP-1 Medicines Available in India 2026: Complete Brand Names, Molecules and Price Comparison
By Dr. Moxit Shah, DM Endocrinology
Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Ahmedabad
India price and availability review: 17 November 2026. Prices are indicative, not quotations.
Which GLP-1 medicines are available in India in 2026, and what do they cost? The choices have expanded dramatically. Alongside Ozempic, Wegovy, Rybelsus, Mounjaro, Victoza and Trulicity, several Indian companies introduced semaglutide medicines after patent expiry in March 2026. Patients now encounter many different brands, doses, injection devices and price points.
This guide compares GLP-1 receptor agonists—semaglutide, liraglutide and dulaglutide—alongside tirzepatide, a dual GIP/GLP-1 receptor agonist. It provides major brand names, publicly reported Indian prices, approved-use distinctions, and key safety considerations.
Important: A brand’s starting price is not necessarily its long-term treatment cost. The approved use may also differ between brands containing the same molecule. All these medicines require appropriate medical prescribing and monitoring.
GLP-1 medicines available in India: molecule-wise summary
| Molecule | Recognized Indian brands | How taken | Indicative cost |
|---|---|---|---|
| Semaglutide injection | Ozempic, Extensior, Wegovy, Poviztra; multiple Indian semaglutide brands | Once weekly | About ₹1,290–₹16,400 per four weekly doses, depending on brand, strength and pack |
| Semaglutide tablet | Rybelsus, Obeda tablets; Semalix tablet formulations | Once daily | Obeda ₹2,970–₹6,750 per 30 tablets; Rybelsus approximately ₹8,916–₹10,884 per 30 tablets |
| Tirzepatide (dual GIP/GLP-1) | Mounjaro, Yurpeak | Once weekly | About ₹13,125–₹25,781 for four weekly doses |
| Liraglutide | Victoza; Lirafit, Erly, Gliptoza, Lyrato | Once daily injection | One 18 mg pen approximately ₹2,086–₹4,991; the number of pens used each month depends on the prescribed daily dose |
| Dulaglutide | Trulicity; Aplevant listings | Once weekly injection | Approximately ₹11,338 for four weekly doses based on commonly listed packs |
How to read prices: The weekly-injection figures refer to a pack or supply covering four weekly doses, not a 30- or 31-day calendar month. Tablets are compared for 30 daily doses. Liraglutide prices are per pen and must be multiplied by the number of pens needed. Some newer brands have published launch estimates rather than independently verified current pharmacy MRPs; any uncertainty is identified below.
1. Semaglutide injections in India: Ozempic, Wegovy, Poviztra and generics
Semaglutide activates the GLP-1 receptor, improving glucose-dependent insulin secretion and reducing appetite. Different semaglutide products can have different approved indications. For example, Ozempic is used for type 2 diabetes while Wegovy is a chronic weight-management brand. Do not assume every generic has exactly the same licensed indications.
Originator and partner semaglutide brands
| Brand | Company | Indian use or positioning | Indicative price for four weekly doses |
|---|---|---|---|
| Ozempic | Novo Nordisk | Type 2 diabetes | ₹5,660 (0.25 mg), ₹8,100 (0.5 mg), ₹9,100 (1 mg) |
| Extensior | Abbott / Novo Nordisk collaboration | Type 2 diabetes; co-brand of Ozempic | Verify current brand- and strength-specific MRP; no independent price confirmed for this article |
| Wegovy | Novo Nordisk | Chronic weight management | ₹5,660 (0.25 mg), ₹8,100 (0.5 mg), ₹9,100 (1 mg), ₹12,750 (1.7 mg), ₹16,400 (2.4 mg) |
| Poviztra | Emcure, with Novo Nordisk | Chronic weight management; partner brand | ₹3,999 (0.25 mg), ₹4,999 (0.5 mg), ₹5,999 (1 mg), ₹7,999 (1.7 mg), ₹8,999 (2.4 mg) |
These values reflect publicly announced April 2026 price revisions and later pharmacy price checks. They are not guarantees of availability or the final bill on a given date. References: Novo Nordisk price revision report; Emcure’s official Poviztra price announcement; Abbott Extensior announcement.
Indian generic semaglutide brands and expected prices
India’s semaglutide market changed after key patent protection expired on 20 March 2026. A growing number of manufacturers launched products under different brand names. The following list includes more than 20 publicly identified brands; the market is evolving, so it is not a guarantee that every approved brand or newly launched SKU is included.
| Manufacturer / marketer | Brand names identified in India | Indicative price information |
|---|---|---|
| Sun Pharma | Sematrinity, Noveltreat | Sematrinity approximately ₹3,000–₹5,200 for four weeks; Noveltreat approximately ₹3,600–₹8,000 for four weeks (company’s March 2026 launch rates) |
| Dr. Reddy’s | Obeda injection | Approximately ₹4,200 for four weeks at launch |
| Zydus | Semaglyn, Mashema, Alterme | Launch reporting around ₹2,200 at certain starting regimens; check the cartridge strength and device separately |
| Lupin (Zydus partnership) | Semanext, Livarise | Individual brand-and-strength MRP not reliably verified here |
| Torrent | Sembolic, Semalix | Some injectable launch reports indicate approximately ₹4,000 for four weeks; oral product pricing varies |
| Alkem | Semasize, Obesema, Hepaglide | Reported starting treatment costs around ₹1,800 for four weekly doses; strength and presentation matter |
| Glenmark | GLIPIQ | Reported vial starting costs around ₹1,300 for four weeks; pen prices may differ |
| Natco | Semanat, Semafull | Reported multidose-vial starting cost around ₹1,290 for approximately four weeks; confirm the available strength and pack |
| Eris (Natco marketing partnership) | Sundae | Reported starting range around ₹1,290 for four weeks; confirm with pharmacy |
| USV | Usema | Current dose-specific price not independently confirmed |
| MSN Laboratories | Semabest | Current dose-specific price not independently confirmed |
| Corona Remedies | Wyntide | Current dose-specific price not independently confirmed |
Why the prices differ: One box may contain a single weekly injection, while another includes a multi-dose pen or vial. A label such as “2 mg” may mean the total amount in the device, not the weekly injection dose. Devices are not automatically interchangeable. Some Indian medicines have approval for type 2 diabetes, some for weight management, and some for both; check each particular product’s Indian prescribing information.
Sun Pharma published the brand indications and launch price ranges in its 21 March 2026 exchange filing. Zydus confirmed its three brand names in an official release. Additional public brand listings and pharmacy-reported price ranges are summarized in GLP Guidebook and MetaGO’s November 2026 brand review.
2. Semaglutide tablets: Rybelsus, Obeda and other oral brands
Oral semaglutide is a daily GLP-1 medicine used for type 2 diabetes in India. It is not equivalent, milligram for milligram, to weekly semaglutide injections. The administration instructions are also important: oral semaglutide generally needs to be taken on an empty stomach with a small amount of water, followed by the specified waiting period before eating, drinking or taking other oral medicines, according to its own label.
| Oral brand | Typical strengths | Indicative price for 30 daily tablets |
|---|---|---|
| Rybelsus (Novo Nordisk) | 3, 7, 14 mg | Approximately ₹8,916 (3 mg), ₹9,900 (7 mg), and ₹10,884 (14 mg) based on listed 10-tablet strip MRPs |
| Obeda tablets (Dr. Reddy’s) | 3, 7, 14 mg | ₹2,970 (3 mg), ₹4,050 (7 mg), ₹6,750 (14 mg), calculated from the manufacturer’s announced ₹99, ₹135 and ₹225 per tablet |
| Semalix (Torrent; oral presentations) | Check pack label | Product-specific retail MRP not independently confirmed for this article |
Obeda tablet prices are based on Dr. Reddy’s 20 May 2026 launch announcement. Rybelsus prices are calculated from public pharmacy-listed MRPs. The Indian approval for these oral formulations is for type 2 diabetes—not a blanket approval for weight-loss treatment.
3. Tirzepatide in India: Mounjaro and Yurpeak
Tirzepatide is a dual GIP/GLP-1 receptor agonist, rather than a conventional GLP-1-only medicine. In India, Mounjaro is marketed by Eli Lilly and Yurpeak is distributed by Cipla under a partnership; both contain tirzepatide. As of this price review, no authorised Indian generic tirzepatide product was confirmed.
| Weekly dose | Approx. Mounjaro KwikPen MRP (four doses) |
|---|---|
| 2.5 mg | ₹13,125 |
| 5 mg | ₹16,406 |
| 7.5 mg | ₹20,625 |
| 10 mg | ₹20,625 |
| 12.5 mg | ₹25,781 |
| 15 mg | ₹25,781 |
Mounjaro may also be supplied as a single-dose vial; a vial is one weekly dose, not four. For example, a 2.5 mg vial has been listed near ₹3,281 and a 5 mg vial near ₹4,102. Approximate Yurpeak KwikPen prices have been reported in a similar range, but the current MRP should be checked separately for the prescribed Yurpeak strength.
Source: Apollo Pharmacy pack listings; Yurpeak India price review.
4. Liraglutide: Victoza, Lirafit and Indian alternatives
Liraglutide is an earlier GLP-1 receptor agonist given as a daily injection. Brand names publicly identified in India include Victoza (Novo Nordisk), Lirafit (Glenmark) and Erly, Gliptoza and Lyrato (Eris). The products available here have primarily been marketed for type 2 diabetes. The separate international 3 mg weight-management brand Saxenda is not currently marketed in India according to October 2026 pharmacy checks.
A standard liraglutide pen holds 18 mg. Therefore, at 0.6 mg/day, one pen lasts 30 days; at 1.2 mg/day, two pens are required; and at 1.8 mg/day, three pens are required. Indicative pen MRPs: Victoza about ₹4,991, Lirafit about ₹2,086, and Erly about ₹2,063. At a prescribed 1.2 mg/day, the estimated 30-day drug cost is about ₹9,982 for Victoza or ₹4,172 for Lirafit. These are illustrative calculations, not dose recommendations.
Source: Liraglutide Indian brand and MRP review, October 2026.
5. Dulaglutide: Trulicity and Aplevant
Dulaglutide is a once-weekly GLP-1 receptor agonist used for type 2 diabetes. Indian pharmacy listings include Trulicity and Aplevant, with 0.75 mg and 1.5 mg strengths in commonly listed presentations.
The indicative listed price is approximately ₹5,669 for two pens, or ₹11,338 for four weekly injections. Stock and exact presentation vary. Unlike products specifically approved for chronic weight management, these brands should not be assumed to have that indication.
Source: Apollo Pharmacy dulaglutide product listings.
What about exenatide, lixisenatide and older GLP-1 medicines?
Exenatide is an older GLP-1 receptor agonist historically sold under brands such as Byetta, Exapride and Exanple. Pharmacy listings for some brands still exist, but consistent current nationwide stock and directly comparable four-week prices could not be verified for this review. Exenatide extended-release formulations also belong to the older drug class but are not consistently available in routine Indian pharmacy channels.
Lixisenatide is another older GLP-1 molecule, including its use in certain fixed-ratio insulin combinations in international markets. Current standalone Indian launch and retail-pricing status could not be reliably established. These products are listed for completeness, not as readily obtainable alternatives in Ahmedabad.
Which future GLP-1 medicines are not yet available in India?
Several newer molecules have attracted attention, but regulatory committee recommendations, international approvals and actual Indian sales are different milestones:
- Orforglipron (Foundayo): an oral GLP-1 medicine approved in the United States in 2026. An Indian CDSCO expert committee recommended permission to import and market certain tablet strengths in May 2026, but this is not the same as a confirmed Indian commercial launch. No reliable Indian MRP or launch date is available for this guide.
- Oral Wegovy 25 mg: a higher-dose oral semaglutide weight-management formulation approved in some other markets, but no verified Indian launch or retail price was found for November 2026.
- Retatrutide: an investigational triple GIP/GLP-1/glucagon receptor agonist. It is not an approved medicine in India or elsewhere as of this review; online claims of injectable retail supply should not be treated as legitimate.
- CagriSema and other investigational combinations: do not yet have a confirmed Indian retail price or regular commercial availability.
Reference: CDSCO Endocrinology Expert Committee minutes, 20 May 2026; Lilly’s investigational retatrutide information.
Which GLP-1 medicine is the least expensive in India?
At some starting doses, Indian generic semaglutide vials have the lowest reported medication cost, with launch prices around ₹1,290–₹1,300 for a four-week supply. However, the cheapest starting pack may not be the cheapest or most appropriate maintenance treatment. The cost changes with dose, the delivery device, local availability, monitoring and whether that particular product is approved for your medical indication.
There is also no guarantee that a monthly price quoted for a lower strength applies at 1.7 mg, 2.4 mg or another higher dose.
How should patients choose between Ozempic, Wegovy, Mounjaro and Indian generics?
The best choice is individualised, and may depend on:
- Goal: type 2 diabetes control, medical weight loss or both.
- Approved indication: confirm whether the specific Indian brand is licensed for the intended use.
- Other conditions: kidney disease, heart disease, gallbladder problems, relevant gastrointestinal disease and pregnancy plans.
- Current treatment: using insulin or sulfonylureas may increase the need for glucose monitoring and dose adjustment because of hypoglycaemia risk.
- Practical considerations: weekly pen, multidose vial or daily tablet; cold-chain handling; storage; training; ongoing cost.
Common adverse effects include nausea, vomiting, constipation and diarrhoea. Serious abdominal pain, severe dehydration or an allergic reaction requires urgent medical assessment. Product-specific precautions may include a history of medullary thyroid cancer or MEN2, depending on the label. These drugs are not substitutes for insulin in type 1 diabetes and should not be used without prescription or monitoring.
Read our related guides on what to eat during GLP-1 treatment, preserving muscle during weight loss, and fatigue and dizziness during treatment.
Frequently asked questions
Are semaglutide and tirzepatide the same medicine?
No. Semaglutide acts at the GLP-1 receptor; tirzepatide acts at GIP and GLP-1 receptors. They have different dose schedules and are not substituted milligram for milligram.
Is there a GLP-1 tablet available in India?
Yes. Oral semaglutide for type 2 diabetes is available under brands including Rybelsus and Obeda tablets, with other products entering the market. Its Indian indication is not automatically chronic weight management.
Does a price of ₹325 mean a full month of GLP-1 medicine costs ₹325?
No. Some news reports quote a cost per weekly dose. For four weekly doses, the starting estimate could be around ₹1,300, and higher doses or other pack formats may cost more.
Is there a generic Mounjaro in India?
No authorised generic tirzepatide launch was confirmed for this November 2026 review. Mounjaro and Yurpeak are Lilly-manufactured tirzepatide brands.
Can patients switch from a branded pen to a generic vial on their own?
No. Even when the molecule is the same, the concentration, pen or vial, delivered dose and instructions may differ. A clinician must verify the exact new product and provide device training.
What should I verify before buying a GLP-1 medicine?
Use a legitimate licensed pharmacy with a valid prescription. Verify brand, active molecule, approved indication, pack strength, number of doses, expiry, batch details and storage instructions. Avoid unfamiliar online offers and unusually inexpensive unverified products.
GLP-1 treatment and medical weight loss in Ahmedabad
At Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Dr. Moxit Shah (DM Endocrinology) provides individualized assessment of diabetes and weight-loss medicines, treatment choices, dose escalation and long-term monitoring. For patients comparing semaglutide, tirzepatide or other GLP-1 therapies, the aim is to choose an appropriate medicine based on medical need—not just the lowest advertised price.
Dr. Moxit Shah, DM Endocrinology
Vishuddha Diabetes, Thyroid, Weight Loss Clinic
104–105, Elite Magnum, Bhuyangdev Cross Road, Opp. Utsav Elegance, Vardhmannagar Society, Ghatlodiya, Memnagar, Ahmedabad, Gujarat 380061, India
For appointments: +91 99799 92797
Pricing sources and review notes
Prices were cross-checked against Novo Nordisk’s April 2026 price revision reporting, Emcure’s April 2026 release, Sun Pharma’s March 2026 release, Dr. Reddy’s oral launch, Apollo Pharmacy, PharmEasy and the India GLP-1 MRP comparison. Not all brands have reliable public prices at every strength. Launch reports and pharmacy-listed MRPs may change without notice.
Last reviewed: 17 November 2026. Price note: All rupee amounts are indicative Indian price information, not an offer to sell, a future-price guarantee or a prescription recommendation.
Medical disclaimer: This article is for general education. GLP-1 medicines and tirzepatide must be prescribed and monitored by an appropriately qualified healthcare professional. Medicine availability, approved indications and patient eligibility should be verified from the current Indian product label. Do not start, stop, combine or switch therapies independently.
